Restless Legs Syndrome
Although the research found opioid use to have a favorable risk-benefit ratio, other avenues of treatment should be considered before opioid prescription including addressing iron stores and combination therapy.
In this case, a 57-year-old Caucasian woman presented with hypersomnolence and altered mental status after having ingested 20-30 diphenhydramine 25mg tablets.
The Food and Drug Administration (FDA) has approved labeling updates regarding dosage and warnings for Requip (ropinirole; GlaxoSmithKline) tablets.
Opioids appeared to be efficacious for treating symptoms of restless leg syndrome (RLS) but there is no definitive evidence regarding the issue of safety, a study published in Cochrane Database of Systematic Reviews concluded.
For patients with severe restless legs syndrome (RLS), gabapentin enacarbil (GEn) was shown to significantly improve RLS symptoms and the consequences of these symptoms.
Pregabalin may help improve symptoms of restless legs syndrome (RLS) and decrease sleep disturbances, according to a recent study in Annals of Pharmacotherapy.
A recent study published in CNS Drugs concluded that gabapentin enacarbil (GEn) taken once daily significantly improved quality of life in adults with moderate-to-severe primary restless legs syndrome (RLS) across all study time points.
Gabapentin enacarbil (GEn) taken once daily, was shown to significantly improve pain associated with moderate-to-severe restless legs syndrome (RLS) in adults, when compared to placebo.
Sensory Medical announced that the FDA has granted commercial clearance for Relaxis, the first nonpharmacological medical device to improve the quality of sleep in patients with primary Restless Legs Syndrome (RLS).
For patients with restless legs syndrome (RLS), pregabalin treatment is associated with improved treatment outcomes versus placebo and with lower augmentation than that seen with 0.5mg pramipexole.
Willis-Ekbom disease, otherwise known as restless legs syndrome, is a neurologic disorder that affects up to 10% of Americans. Individuals with RLS develop irresistible urges to move their legs accompanied by unusual or unpleasant sensations in the legs.
GlaxoSmithKline is currently experiencing a shortage of Horizant 600mg extended-release tablets, according to the FDA. Horizant is a prodrug of gabapentin that is indicated for postherpetic neuralgia and for moderate-to-severe primary restless legs syndrome in adults.
In patients with restless legs syndrome, dopamine agonists and calcium channel alpha-2-delta ligands are effective in reducing symptoms and improving sleep and quality of life, although adverse events are common and often lead to treatment withdrawals.
The FDA notified healthcare professionals about a possible increased risk of heart failure with Mirapex (pramipexole tablets; Boehringer Ingelheim).
UCB announced that Neupro (rotigotine transdermal system) is now available as a once-daily patch for the treatment of signs and symptoms of early and advanced stage idiopathic Parkinson's disease (PD) and moderate-to-severe primary restless legs syndrome (RLS).
UCB announced that the FDA has approved Neupro (rotigotine transdermal system) for the treatment of the signs and symptoms of advanced stage idiopathic Parkinson's disease (PD) and as a treatment for moderate-to-severe primary restless legs syndrome (RLS).
Pfizer announced results from its Phase 3 study of Lyrica (pregabalin) for the treatment of restless leg syndrome (RLS).
GlaxoSmithKline and XenoPort announced that the FDA has approved Horizant (gabapentin enacarbil extended-release tablets) for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS) in adults.